Wegovy website NON-GLP WEIGHT-LOSS INJECTION IMPRESSES IN TRIAL November 2025 Eli Lilly reported impressive results for an experimental once-weekly weight-loss injection called eloralintide that is not part of the GLP class
The medication may look, smell, and feel normal while delivering significantly reduced efficacy
Supporting this, a recent prospective cohort study has confirmed that significant iron deposition in the caudate nucleus and putamen of patients with T2DM is significantly associated with diminished cognitive performance, manifesting as slower processing speed, declined memory, and poorer executive function, thereby indicating a negative correlation between the degree of iron accumulation in these nuclei and overall cognitive ability (Cheng et al., 2025)
The specific protocol depends on whether its used for diabetes (e.g., Ozempic) or weight loss (e.g., Wegovy)
This is one of the most important parts of the conversation